targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000041880 | EFO_0000616 | NCT01900028 | Completed | 1 | 2013-10-01 | null | null | null | null | null | 1,202,590,843,507 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01900028 | Completed | 1 | 2013-10-01 | null | null | null | null | null | 1,202,590,843,507 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01900028 | Completed | 1 | 2013-10-01 | null | null | null | null | null | 1,202,590,843,507 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01900028 | Completed | 1 | 2013-10-01 | null | null | null | null | null | 1,202,590,843,507 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01900028 | Completed | 1 | 2013-10-01 | null | null | null | null | null | 1,202,590,843,507 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01900028 | Completed | 1 | 2013-10-01 | null | null | null | null | null | 1,202,590,843,507 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01900028 | Completed | 1 | 2013-10-01 | null | null | null | null | null | 1,202,590,843,507 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01017640 | Completed | 1 | 2009-10-01 | null | null | null | null | null | 1,236,950,582,497 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01017640 | Completed | 1 | 2009-10-01 | null | null | null | null | null | 1,236,950,582,497 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01017640 | Completed | 1 | 2009-10-01 | null | null | null | null | null | 1,236,950,582,497 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01017640 | Completed | 1 | 2009-10-01 | null | null | null | null | null | 1,236,950,582,497 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01017640 | Completed | 1 | 2009-10-01 | null | null | null | null | null | 1,236,950,582,497 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01017640 | Completed | 1 | 2009-10-01 | null | null | null | null | null | 1,236,950,582,497 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01017640 | Completed | 1 | 2009-10-01 | null | null | null | null | null | 1,236,950,582,497 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01017640 | Completed | 1 | 2009-10-01 | null | null | null | null | null | 1,236,950,582,497 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01017640 | Completed | 1 | 2009-10-01 | null | null | null | null | null | 1,236,950,582,497 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01009190 | Completed | 1 | 2010-02-01 | null | null | null | null | null | 1,279,900,255,921 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01009190 | Completed | 1 | 2010-02-01 | null | null | null | null | null | 1,279,900,255,921 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01009190 | Completed | 1 | 2010-02-01 | null | null | null | null | null | 1,279,900,255,921 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01009190 | Completed | 1 | 2010-02-01 | null | null | null | null | null | 1,279,900,255,921 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01009190 | Completed | 1 | 2010-02-01 | null | null | null | null | null | 1,279,900,255,921 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01009190 | Completed | 1 | 2010-02-01 | null | null | null | null | null | 1,279,900,255,921 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01009190 | Completed | 1 | 2010-02-01 | null | null | null | null | null | 1,279,900,255,921 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01009190 | Completed | 1 | 2010-02-01 | null | null | null | null | null | 1,279,900,255,921 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01009190 | Completed | 1 | 2010-02-01 | null | null | null | null | null | 1,279,900,255,921 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02631733 | Active, not recruiting | 1 | 2016-07-15 | null | null | null | null | null | 1,288,490,188,922 | Other - Revision to study design | Phase 1 | 15/07/2016 | Suspended | 07/07/2021 | 01/07/2022 | Study_Design | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02631733 | Active, not recruiting | 1 | 2016-07-15 | null | null | null | null | null | 1,288,490,188,922 | Other - Revision to study design | Phase 1 | 15/07/2016 | Suspended | 07/07/2021 | 01/07/2022 | Study_Design | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02631733 | Active, not recruiting | 1 | 2016-07-15 | null | null | null | null | null | 1,288,490,188,922 | Other - Revision to study design | Phase 1 | 15/07/2016 | Suspended | 07/07/2021 | 01/07/2022 | Study_Design | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02631733 | Active, not recruiting | 1 | 2016-07-15 | null | null | null | null | null | 1,288,490,188,922 | Other - Revision to study design | Phase 1 | 15/07/2016 | Suspended | 07/07/2021 | 01/07/2022 | Study_Design | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02631733 | Active, not recruiting | 1 | 2016-07-15 | null | null | null | null | null | 1,288,490,188,922 | Other - Revision to study design | Phase 1 | 15/07/2016 | Suspended | 07/07/2021 | 01/07/2022 | Study_Design | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02631733 | Active, not recruiting | 1 | 2016-07-15 | null | null | null | null | null | 1,288,490,188,922 | Other - Revision to study design | Phase 1 | 15/07/2016 | Suspended | 07/07/2021 | 01/07/2022 | Study_Design | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02631733 | Active, not recruiting | 1 | 2016-07-15 | null | null | null | null | null | 1,288,490,188,922 | Other - Revision to study design | Phase 1 | 15/07/2016 | Suspended | 07/07/2021 | 01/07/2022 | Study_Design | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02631733 | Active, not recruiting | 1 | 2016-07-15 | null | null | null | null | null | 1,288,490,188,922 | Other - Revision to study design | Phase 1 | 15/07/2016 | Suspended | 07/07/2021 | 01/07/2022 | Study_Design | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT02631733 | Active, not recruiting | 1 | 2016-07-15 | null | null | null | null | null | 1,288,490,188,922 | Other - Revision to study design | Phase 1 | 15/07/2016 | Suspended | 07/07/2021 | 01/07/2022 | Study_Design | Neutral | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,288,490,189,416 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,288,490,189,416 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,288,490,189,416 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,288,490,189,416 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,288,490,189,416 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,288,490,189,416 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,288,490,189,416 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,288,490,189,416 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 4 | null | null | null | Phase IV | Phase III+ | Phase II+ | 1,288,490,189,416 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03521037 | Completed | 1 | 2018-02-27 | null | null | null | null | null | 1,425,929,144,046 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03521037 | Completed | 1 | 2018-02-27 | null | null | null | null | null | 1,425,929,144,046 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03521037 | Completed | 1 | 2018-02-27 | null | null | null | null | null | 1,425,929,144,046 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03521037 | Completed | 1 | 2018-02-27 | null | null | null | null | null | 1,425,929,144,046 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03521037 | Completed | 1 | 2018-02-27 | null | null | null | null | null | 1,425,929,144,046 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03521037 | Completed | 1 | 2018-02-27 | null | null | null | null | null | 1,425,929,144,046 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03521037 | Completed | 1 | 2018-02-27 | null | null | null | null | null | 1,425,929,144,046 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03521037 | Completed | 1 | 2018-02-27 | null | null | null | null | null | 1,425,929,144,046 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03521037 | Completed | 1 | 2018-02-27 | null | null | null | null | null | 1,425,929,144,046 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01617928 | Completed | 1 | 2012-05-01 | null | null | null | null | null | 1,468,878,815,665 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01617928 | Completed | 1 | 2012-05-01 | null | null | null | null | null | 1,468,878,815,665 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01617928 | Completed | 1 | 2012-05-01 | null | null | null | null | null | 1,468,878,815,665 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01617928 | Completed | 1 | 2012-05-01 | null | null | null | null | null | 1,468,878,815,665 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01617928 | Completed | 1 | 2012-05-01 | null | null | null | null | null | 1,468,878,815,665 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01617928 | Completed | 1 | 2012-05-01 | null | null | null | null | null | 1,468,878,815,665 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01617928 | Completed | 1 | 2012-05-01 | null | null | null | null | null | 1,468,878,815,665 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01617928 | Completed | 1 | 2012-05-01 | null | null | null | null | null | 1,468,878,815,665 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01617928 | Completed | 1 | 2012-05-01 | null | null | null | null | null | 1,468,878,815,665 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01827384 | Active, not recruiting | 2 | 2013-12-31 | null | null | null | null | Phase II+ | 1,580,547,966,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01827384 | Active, not recruiting | 2 | 2013-12-31 | null | null | null | null | Phase II+ | 1,580,547,966,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01827384 | Active, not recruiting | 2 | 2013-12-31 | null | null | null | null | Phase II+ | 1,580,547,966,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01827384 | Active, not recruiting | 2 | 2013-12-31 | null | null | null | null | Phase II+ | 1,580,547,966,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01827384 | Active, not recruiting | 2 | 2013-12-31 | null | null | null | null | Phase II+ | 1,580,547,966,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01827384 | Active, not recruiting | 2 | 2013-12-31 | null | null | null | null | Phase II+ | 1,580,547,966,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01827384 | Active, not recruiting | 2 | 2013-12-31 | null | null | null | null | Phase II+ | 1,580,547,966,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01827384 | Active, not recruiting | 2 | 2013-12-31 | null | null | null | null | Phase II+ | 1,580,547,966,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01827384 | Active, not recruiting | 2 | 2013-12-31 | null | null | null | null | Phase II+ | 1,580,547,966,622 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04236414 | Recruiting | 1 | 2020-01-14 | null | null | null | null | null | 1,589,137,900,288 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04236414 | Recruiting | 1 | 2020-01-14 | null | null | null | null | null | 1,589,137,900,288 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04236414 | Recruiting | 1 | 2020-01-14 | null | null | null | null | null | 1,589,137,900,288 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04236414 | Recruiting | 1 | 2020-01-14 | null | null | null | null | null | 1,589,137,900,288 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04236414 | Recruiting | 1 | 2020-01-14 | null | null | null | null | null | 1,589,137,900,288 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04236414 | Recruiting | 1 | 2020-01-14 | null | null | null | null | null | 1,589,137,900,288 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04236414 | Recruiting | 1 | 2020-01-14 | null | null | null | null | null | 1,589,137,900,288 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04236414 | Recruiting | 1 | 2020-01-14 | null | null | null | null | null | 1,589,137,900,288 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT04236414 | Recruiting | 1 | 2020-01-14 | null | null | null | null | null | 1,589,137,900,288 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01434316 | Recruiting | 1 | 2011-11-01 | null | null | null | null | null | 1,589,137,900,822 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01434316 | Recruiting | 1 | 2011-11-01 | null | null | null | null | null | 1,589,137,900,822 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01434316 | Recruiting | 1 | 2011-11-01 | null | null | null | null | null | 1,589,137,900,822 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01434316 | Recruiting | 1 | 2011-11-01 | null | null | null | null | null | 1,589,137,900,822 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01434316 | Recruiting | 1 | 2011-11-01 | null | null | null | null | null | 1,589,137,900,822 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01434316 | Recruiting | 1 | 2011-11-01 | null | null | null | null | null | 1,589,137,900,822 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01434316 | Recruiting | 1 | 2011-11-01 | null | null | null | null | null | 1,589,137,900,822 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01434316 | Recruiting | 1 | 2011-11-01 | null | null | null | null | null | 1,589,137,900,822 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01434316 | Recruiting | 1 | 2011-11-01 | null | null | null | null | null | 1,589,137,900,822 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516438 | Completed | 1 | 2007-07-01 | null | null | null | null | null | 1,623,497,639,869 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516438 | Completed | 1 | 2007-07-01 | null | null | null | null | null | 1,623,497,639,869 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516438 | Completed | 1 | 2007-07-01 | null | null | null | null | null | 1,623,497,639,869 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516438 | Completed | 1 | 2007-07-01 | null | null | null | null | null | 1,623,497,639,869 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516438 | Completed | 1 | 2007-07-01 | null | null | null | null | null | 1,623,497,639,869 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516438 | Completed | 1 | 2007-07-01 | null | null | null | null | null | 1,623,497,639,869 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516438 | Completed | 1 | 2007-07-01 | null | null | null | null | null | 1,623,497,639,869 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516438 | Completed | 1 | 2007-07-01 | null | null | null | null | null | 1,623,497,639,869 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT00516438 | Completed | 1 | 2007-07-01 | null | null | null | null | null | 1,623,497,639,869 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03057145 | Completed | 1 | 2017-03-10 | null | null | null | null | null | 1,632,087,572,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03057145 | Completed | 1 | 2017-03-10 | null | null | null | null | null | 1,632,087,572,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03057145 | Completed | 1 | 2017-03-10 | null | null | null | null | null | 1,632,087,572,597 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |